Skip to main content
Premium Trial:

Request an Annual Quote

Puerto Rico to Build Genomics Facility as Part of New Biotech Hub

NEW YORK (GenomeWeb News) - Genomic technologies will be a focus of a new biotechnology hub being build in Puerto Rico,  the island’s governor said today.
Calling the US territory a “Bio Island,” Anibal Acevedo Vilau said the molecular science facility would be a joint venture of the Puerto Rico, the US National Institutes of Health, and the University of Puerto Rico.
Along with genomics, the facility will study nanotechnology, biology, molecular neurosciences, and infectious disease prevention research.
The biotechnology hub will also include the University of Puerto Rico Cancer Center, a joint venture with the M.D. Anderson Cancer Center. The center will study cancer prevention and treatment specifically for the Hispanic community.
Puerto Rico also established the Science and Technology Trust to provide ongoing funding for infrastructure advancements and research and development projects.
Puerto Rico’s biotechnology sector has more than 2 million square feet of manufacturing space and has generated more than $3.5 billion in capital investments, the governor said.
The remarks were made as part of the second annual Biotechnology Week on Puerto Rico, which coincided with the third annual Caribbean and Latin American Biotechnology Congress.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.